Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is suited for growth investing. Investors should of course do their own research, but we spotted CATALYST PHARMACEUTICALS INC showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

What matters for canslim investors.

• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), CPRX highlights its ability to generate increasing profitability, showcasing a 41.94% growth.
• The q2q revenue growth of 28.26% of CPRX highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
• The EPS of CPRX has shown consistent growth over a 3-year period, indicating the company's ability to generate increasing earnings over time.
• CPRX has a healthy Return on Equity(ROE) of 22.52%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
• The Relative Strength (RS) of CPRX has been consistently solid, with a current 93.01 rating. This highlights the stock's ability to exhibit sustained price strength and signifies its competitive advantage.
• CPRX maintains a healthy Debt-to-Equity ratio of 0.0. This indicates the company's conservative capital structure and signifies its ability to effectively manage debt obligations while maintaining a strong equity position.
• With 83.75% of the total shares held by institutional investors, CPRX showcases a healthy distribution of ownership. This suggests a mix of institutional and retail investors, fostering a dynamic market for the stock.

What is the technical picture of CPRX telling us.

ChartMill assigns a Technical Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple technical indicators and properties.

Overall CPRX gets a technical rating of 7 out of 10. In the last year, CPRX was one of the better performers, but we do observe some doubts in the very recent evolution.

• The short term is neutral, but the long term trend is still positive. Not much to worry about for now.
• When comparing the yearly performance of all stocks, we notice that CPRX is one of the better performing stocks in the market, outperforming 93% of all stocks. On top of that, CPRX also shows a nice and consistent pattern of rising prices.
• CPRX is part of the Biotechnology industry. There are 568 other stocks in this industry. CPRX outperforms 90% of them.
• CPRX is currently trading in the middle of its 52 week range. This is in line with the S&P500 Index, which is also trading in the middle of its range.
• In the last month CPRX has a been trading in the 20.40 - 26.16 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Check the latest full technical report of CPRX for a complete technical analysis.

What else is there to say on the fundamentals of CPRX?

ChartMill employs a sophisticated system to assign a Fundamental Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple fundamental indicators and properties.

Overall CPRX gets a fundamental rating of 8 out of 10. We evaluated CPRX against 568 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.

Our latest full fundamental report of CPRX contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our CANSLIM screen.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.